Journal
CELL HOST & MICROBE
Volume 18, Issue 1, Pages 86-95Publisher
CELL PRESS
DOI: 10.1016/j.chom.2015.06.009
Keywords
-
Categories
Funding
- U.S. National Institutes of Health [R01 AI114816, K08 AI103038, F32 AI096833, T32 HL007751, T32 5T32AI007151-33, U54 AI057157, R01 AI104545]
- NIH [HHSN272200900055C]
- Elizabeth B. Lamb Center for Pediatric Research
- Infectious Diseases Society of America Education and Research Foundation
- National Foundation for Infectious Diseases Young Investigator Award in Vaccine Development
- National Center for Research Resources [UL1 RR024975-01]
- National Center for Advancing Translational Sciences [2 UL1 TR000445-06]
- Pfizer
Ask authors/readers for more resources
Chikungunya virus (CHIKV) is a mosquito-transmitted RNA virus that causes acute febrile infection associated with polyarthralgia in humans. Mechanisms of protective immunity against CHIKV are poorly understood, and no effective therapeutics or vaccines are available. We isolated and characterized human monoclonal antibodies (mAbs) that neutralize CHIKV infectivity. Among the 30 mAbs isolated, 13 had broad and ultrapotent neutralizing activity (IC50 < 10 ng/ml), and all of these mapped to domain A of the E2 envelope protein. Potent inhibitory mAbs blocked post-attachment steps required for CHIKV membrane fusion, and several were protective in a lethal challenge model in immunocompromised mice, even when administered at late time points after infection. These highly protective mAbs could be considered for prevention or treatment of CHIKV infection, and their epitope location in domain A of E2 could be targeted for rational structure-based vaccine development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available